Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multigene HIV-1 plasmid DNA vaccine
- Development stage
- Unknown
- Lead developer
- Karolinska Institutet
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The multigene HIV-1 plasmid DNA vaccine (HIVIS DNA) is an investigational DNA-based vaccine developed by the Swedish Institute for Infectious Disease Control (SMI), Karolinska Institutet, and Karolinska University Hospital. It is composed of seven plasmids encoding multiple HIV-1 antigens, including gp160 Env (subtypes A, B, and C), Rev (subtype B), Gag (subtypes A and B), and a mutated reverse transcriptase (RTmut, subtype B). This multigene, multiclade design is intended to elicit broad cellular (CD8+ T-cell) and humoral (antibody) immune responses against HIV-1. In clinical trials, such as the Phase I/II HIVIS 03 trial in Tanzania and the Phase I HVRRICANE trial in South Africa, it has been evaluated as a priming vaccine followed by boosting with recombinant Modified Vaccinia Ankara (MVA-CMDR) vector vaccines. The vaccine is typically administered intradermally using a needle-free injection device.
- Other names
- HIVIS DNA vaccineHIVIS-DNA vaccinemultigene HIV-1 DNA vaccinemultigene, multiclade HIV-1 DNA vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)Rev (HIV-1 Rev)Human immunodeficiency virus 1 reverse transcriptase mutantTLR9 (Toll-like receptor 9)Env (HIV-1 envelope glycoprotein)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on multigene HIV-1 plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multigene HIV-1 plasmid DNA vaccine.